Combination of Neoadjuvant Transcatheter Arterial Chemoembolization and Orthotopic Liver Transplantation for the Treatment of Cirrhotomimetic Hepatocellular Carcinoma

Peiman Habibollahi, Sara P. Shamchi, Rashmi Tondon, Brett L. Ecker, Terence P. Gade, Stephen Hunt, Michael C. Soulen, Emma E. Furth, Matthew H. Levine, Gregory Nadolski

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC. Materials and Methods: All patients with pathologically proven CMM HCC who underwent bridging transcatheter arterial chemoembolization before OLT between 2007 and 2013 (n = 23) were retrospectively compared with a control group of patients with pathologically proven non-CMM HCC (n = 46). Results: There were 29 tumors in the CMM HCC group and 64 tumors in the non-CMM group identified and treated. Objective response rate on MR imaging at 1 and 3 months after transcatheter arterial chemoembolization for CMM HCC tumors (including patients with complete and partial response) was 93.1% and 86.4% compared with 85.2% and 93.2% for non-CMM tumors without statistically significant difference (P =.54 and P =.09, respectively). Pathologic study of liver explants showed complete tumor necrosis in 62.3% of non-CMM tumors (38/61) compared with 10.3% of CMM tumors (3/29) (P <.0001). Overall 2-year survival after transcatheter arterial chemoembolization and OLT was significantly lower for patients with CMM HCC compared with patients non-CMM HCC (65.2% vs 87%, P =.03). Patients with CMM HCC with extranodular tumor extension involving > 50% of liver parenchyma had worse survival with mean 2-year survival of 402 days ± 102 vs 656 days ± 39 for the remaining patients with CMM HCC (P =.02). Conclusions: Despite similar early imaging response rates, CMM HCC tumors had markedly lower rates of complete pathologic necrosis on liver explants and were associated with reduced survival after OLT compared with conventional HCCs.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume29
Issue number2
DOIs
StatePublished - Feb 2018
Externally publishedYes

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Neoplasms
Therapeutics
Survival
Liver
Necrosis
Control Groups

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Combination of Neoadjuvant Transcatheter Arterial Chemoembolization and Orthotopic Liver Transplantation for the Treatment of Cirrhotomimetic Hepatocellular Carcinoma. / Habibollahi, Peiman; Shamchi, Sara P.; Tondon, Rashmi; Ecker, Brett L.; Gade, Terence P.; Hunt, Stephen; Soulen, Michael C.; Furth, Emma E.; Levine, Matthew H.; Nadolski, Gregory.

In: Journal of Vascular and Interventional Radiology, Vol. 29, No. 2, 02.2018, p. 237-243.

Research output: Contribution to journalArticle

Habibollahi, Peiman ; Shamchi, Sara P. ; Tondon, Rashmi ; Ecker, Brett L. ; Gade, Terence P. ; Hunt, Stephen ; Soulen, Michael C. ; Furth, Emma E. ; Levine, Matthew H. ; Nadolski, Gregory. / Combination of Neoadjuvant Transcatheter Arterial Chemoembolization and Orthotopic Liver Transplantation for the Treatment of Cirrhotomimetic Hepatocellular Carcinoma. In: Journal of Vascular and Interventional Radiology. 2018 ; Vol. 29, No. 2. pp. 237-243.
@article{71b9f1d4cc954bbca3a81dbd096a9e86,
title = "Combination of Neoadjuvant Transcatheter Arterial Chemoembolization and Orthotopic Liver Transplantation for the Treatment of Cirrhotomimetic Hepatocellular Carcinoma",
abstract = "Purpose: To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC. Materials and Methods: All patients with pathologically proven CMM HCC who underwent bridging transcatheter arterial chemoembolization before OLT between 2007 and 2013 (n = 23) were retrospectively compared with a control group of patients with pathologically proven non-CMM HCC (n = 46). Results: There were 29 tumors in the CMM HCC group and 64 tumors in the non-CMM group identified and treated. Objective response rate on MR imaging at 1 and 3 months after transcatheter arterial chemoembolization for CMM HCC tumors (including patients with complete and partial response) was 93.1{\%} and 86.4{\%} compared with 85.2{\%} and 93.2{\%} for non-CMM tumors without statistically significant difference (P =.54 and P =.09, respectively). Pathologic study of liver explants showed complete tumor necrosis in 62.3{\%} of non-CMM tumors (38/61) compared with 10.3{\%} of CMM tumors (3/29) (P <.0001). Overall 2-year survival after transcatheter arterial chemoembolization and OLT was significantly lower for patients with CMM HCC compared with patients non-CMM HCC (65.2{\%} vs 87{\%}, P =.03). Patients with CMM HCC with extranodular tumor extension involving > 50{\%} of liver parenchyma had worse survival with mean 2-year survival of 402 days ± 102 vs 656 days ± 39 for the remaining patients with CMM HCC (P =.02). Conclusions: Despite similar early imaging response rates, CMM HCC tumors had markedly lower rates of complete pathologic necrosis on liver explants and were associated with reduced survival after OLT compared with conventional HCCs.",
author = "Peiman Habibollahi and Shamchi, {Sara P.} and Rashmi Tondon and Ecker, {Brett L.} and Gade, {Terence P.} and Stephen Hunt and Soulen, {Michael C.} and Furth, {Emma E.} and Levine, {Matthew H.} and Gregory Nadolski",
year = "2018",
month = "2",
doi = "10.1016/j.jvir.2017.09.008",
language = "English (US)",
volume = "29",
pages = "237--243",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Combination of Neoadjuvant Transcatheter Arterial Chemoembolization and Orthotopic Liver Transplantation for the Treatment of Cirrhotomimetic Hepatocellular Carcinoma

AU - Habibollahi, Peiman

AU - Shamchi, Sara P.

AU - Tondon, Rashmi

AU - Ecker, Brett L.

AU - Gade, Terence P.

AU - Hunt, Stephen

AU - Soulen, Michael C.

AU - Furth, Emma E.

AU - Levine, Matthew H.

AU - Nadolski, Gregory

PY - 2018/2

Y1 - 2018/2

N2 - Purpose: To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC. Materials and Methods: All patients with pathologically proven CMM HCC who underwent bridging transcatheter arterial chemoembolization before OLT between 2007 and 2013 (n = 23) were retrospectively compared with a control group of patients with pathologically proven non-CMM HCC (n = 46). Results: There were 29 tumors in the CMM HCC group and 64 tumors in the non-CMM group identified and treated. Objective response rate on MR imaging at 1 and 3 months after transcatheter arterial chemoembolization for CMM HCC tumors (including patients with complete and partial response) was 93.1% and 86.4% compared with 85.2% and 93.2% for non-CMM tumors without statistically significant difference (P =.54 and P =.09, respectively). Pathologic study of liver explants showed complete tumor necrosis in 62.3% of non-CMM tumors (38/61) compared with 10.3% of CMM tumors (3/29) (P <.0001). Overall 2-year survival after transcatheter arterial chemoembolization and OLT was significantly lower for patients with CMM HCC compared with patients non-CMM HCC (65.2% vs 87%, P =.03). Patients with CMM HCC with extranodular tumor extension involving > 50% of liver parenchyma had worse survival with mean 2-year survival of 402 days ± 102 vs 656 days ± 39 for the remaining patients with CMM HCC (P =.02). Conclusions: Despite similar early imaging response rates, CMM HCC tumors had markedly lower rates of complete pathologic necrosis on liver explants and were associated with reduced survival after OLT compared with conventional HCCs.

AB - Purpose: To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC. Materials and Methods: All patients with pathologically proven CMM HCC who underwent bridging transcatheter arterial chemoembolization before OLT between 2007 and 2013 (n = 23) were retrospectively compared with a control group of patients with pathologically proven non-CMM HCC (n = 46). Results: There were 29 tumors in the CMM HCC group and 64 tumors in the non-CMM group identified and treated. Objective response rate on MR imaging at 1 and 3 months after transcatheter arterial chemoembolization for CMM HCC tumors (including patients with complete and partial response) was 93.1% and 86.4% compared with 85.2% and 93.2% for non-CMM tumors without statistically significant difference (P =.54 and P =.09, respectively). Pathologic study of liver explants showed complete tumor necrosis in 62.3% of non-CMM tumors (38/61) compared with 10.3% of CMM tumors (3/29) (P <.0001). Overall 2-year survival after transcatheter arterial chemoembolization and OLT was significantly lower for patients with CMM HCC compared with patients non-CMM HCC (65.2% vs 87%, P =.03). Patients with CMM HCC with extranodular tumor extension involving > 50% of liver parenchyma had worse survival with mean 2-year survival of 402 days ± 102 vs 656 days ± 39 for the remaining patients with CMM HCC (P =.02). Conclusions: Despite similar early imaging response rates, CMM HCC tumors had markedly lower rates of complete pathologic necrosis on liver explants and were associated with reduced survival after OLT compared with conventional HCCs.

UR - http://www.scopus.com/inward/record.url?scp=85036671306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036671306&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2017.09.008

DO - 10.1016/j.jvir.2017.09.008

M3 - Article

C2 - 29221923

AN - SCOPUS:85036671306

VL - 29

SP - 237

EP - 243

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 2

ER -